Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Urinalysis instrumentation, 2025

[one_third]

[/one_third]

[one_third]

[/one_third]

[one_third_last]

[/one_third_last]

[wpdatatable id=120]

[one_third]

[/one_third]
[two_third_last]

On value, preanalytics, and personnel in urinalysis

March 2025—Urinalysis reflex rules, reimbursement, instruments, research, and specimen handling and transport are some of what came up in the Jan. 15 roundtable with eight participants online and CAP TODAY publisher Bob McGonnagle leading the discussion. What they told CAP TODAY begins here, and our revised guide to urinalysis instrumentation is here.

In our urinalysis roundtable last year there was emphasis on reflex testing as a solution to some of the need for efficiency in the urinalysis workflow. Of course, people in pharmacy and the infectious disease physicians have different views about reflex criteria in urinalysis. We also talked about the need for working rules in the interest of efficiency and workflow amid automation and artificial intelligence. Lastly, we talked about the science of urinalysis, which seems to be underappreciated in the United States. Jason Anderson, can you comment on the current relevancy of those themes?

Jason M. Anderson, MPH, MT(ASCP), senior product manager, urinalysis solutions IVD product marketing, Sysmex America: Reflex testing, when done appropriately, can provide a host of benefits, from improved laboratory efficiency to more timely information for clinicians and ultimately a higher standard of patient care. Determining optimal reflex algorithms can be a challenge. Laboratory practice in urinalysis is not always standardized. Even within an integrated health network, you might see the use of different cutoffs or reflex rules at different facilities. Establishing reflex rules, agreeing on those with the various stakeholders, and making sure they’re optimized and evidence-based to the specific patient populations served are key.

With the progress of AI, machine learning, and expert system disciplines, in conjunction with increasing evidence-based outcome data, I believe we’ll see a strong emphasis on developing even more powerful and advanced reflex testing algorithms that are population specific in many cases. Add to this that analyzer technology is allowing for greater standardization, sensitivity, and specificity in laboratory testing and I see a recipe for making a positive impact on patient care.

Continue reading …
[/two_third_last]